Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director and other PDMR Dealings
London, August 16, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on August 15, 2019, Charles Sermon, General Counsel, purchased 6355 Ordinary Shares at a price of GBP0.54 per share. Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 6000 Ordinary Shares at a price of GBP0.54 per share. John Richard, Head of Corporate Development at Mereo, purchased 1500 American Depositary Shares (ADSs) at a price of USD3.31 per ADS.
On August 16, 2019 Denise Scots-Knight, Chief Executive Officer of Mereo, also purchased 6000 Ordinary Shares at a price of GBP0.54 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Charles Sermon |
2 |
Reason for the notification |
a) |
Position/status |
General Counsel |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH |
b) |
Nature of the transaction |
PURCHASE |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
GBP0.54 |
6355 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 6355 Aggregated price: GBP0.535 |
e) |
Date of the transaction |
2019-08-15 |
f) |
Place of the transaction |
AIMX |
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Denise Scots-Knight |
2 |
Reason for the notification |
a) |
Position/status |
Chief Executive Officer |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH |
b) |
Nature of the transaction |
PURCHASE |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
GBP0.54 |
6000 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 6000 Aggregated price: GBP0.54 |
e) |
Date of the transaction |
2019-08-15 |
f) |
Place of the transaction |
AIMX |
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Denise Scots-Knight |
2 |
Reason for the notification |
a) |
Position/status |
Chief Executive Officer |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH |
b) |
Nature of the transaction |
PURCHASE |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
GBP0.54 |
6000 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 6000 Aggregated price: GBP0.535 |
e) |
Date of the transaction |
2019-08-16 |
f) |
Place of the transaction |
AIMX |
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
John Richard |
2 |
Reason for the notification |
a) |
Position/status |
Head of Corporate Development |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH |
b) |
Nature of the transaction |
PURCHASE |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
USD3.31 |
1500 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 1500 Aggregated price: USD3.313 |
e) |
Date of the transaction |
2019-08-15 |
f) |
Place of the transaction |
XNMS |